Skip to content

Debt-to-assets at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.4×0.0×
ALN
Alnylam PharmaceuticalsALNY
0.1×0.0×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
0.1×0.0×

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$881.02M+32.6%
Enterprise value$857.94M+36.6%
P/E5.5×
P/S4.6×-99.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Calculated from Arbutus Biopharma Corporation’s reported figures.

Based on the most recent quarter.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's debt-to-assets?
Arbutus Biopharma Corporation (ABUS) reported debt-to-assets of 0× in Q1 2026.
How has Arbutus Biopharma Corporation's debt-to-assets changed year-over-year?
Arbutus Biopharma Corporation's debt-to-assets decreased by 77.5% year-over-year, from 0× to 0×.
What is the long-term trend for Arbutus Biopharma Corporation's debt-to-assets?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's debt-to-assets has grown at a -18.4% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.